Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

reported in the New England Journal of Medicine that patients with COPD and type 2 inflammation who received the biologic agent dupilumab had fewer exacerbations, better lung function, and less severe ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Chronic obstructive pulmonary disease (COPD ... to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease, shortly after ...

The first biologic to enter the COPD market, Dupixent (dupilumab), has paved the way for competitors, demonstrating significant efficacy in reducing exacerbations. Dupixent’s success has ...

Reuters Health Information, March 07, 2024 Dupilumab Earns FDA Priority Review for Add-On COPD Care The first new COPD treatment in a decade showed safety and effectiveness in a subset of patients ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

Fewer than 10% of children or adolescents with peanut allergy passed a desnsitiaztion food challenge after receiving dupilumab for 24 weeks. Image: Adobe Stock “The impact of the findings for ...

Medscape News UK, May 30, 2024 ATS 2024 Dupilumab Improves Outcomes in COPD With Type 2 Inflammation New trial confirmed safety and efficacy of a subcutaneous add-on therapy for uncontrolled COPD.